Goldman Sachs Initiates Coverage of Corteva (CTVA) with Buy Recommendation

Fintel reports that on March 13, 2025, Goldman Sachs initiated coverage of Corteva (NYSE:CTVA) with a Buy recommendation.

Analyst Price Forecast Suggests 19.44% Upside

As of March 4, 2025, the average one-year price target for Corteva is $70.47/share. The forecasts range from a low of $57.57 to a high of $78.75. The average price target represents an increase of 19.44% from its latest reported closing price of $59.00 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Corteva is 19,823MM, an increase of 17.24%. The projected annual non-GAAP EPS is 4.31.

What is the Fund Sentiment?

There are 2,092 funds or institutions reporting positions in Corteva. This is an increase of 69 owner(s) or 3.41% in the last quarter. Average portfolio weight of all funds dedicated to CTVA is 0.32%, an increase of 1.95%. Total shares owned by institutions increased in the last three months by 2.74% to 741,084K shares. The put/call ratio of CTVA is 0.61, indicating a bullish outlook.

What are Other Shareholders Doing?

Capital International Investors holds 23,461K shares representing 3.42% ownership of the company. In its prior filing, the firm reported owning 24,810K shares , representing a decrease of 5.75%. The firm decreased its portfolio allocation in CTVA by 10.33% over the last quarter.

Aristotle Capital Management holds 23,372K shares representing 3.41% ownership of the company. In its prior filing, the firm reported owning 23,731K shares , representing a decrease of 1.54%. The firm increased its portfolio allocation in CTVA by 0.98% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 21,646K shares representing 3.16% ownership of the company. In its prior filing, the firm reported owning 21,794K shares , representing a decrease of 0.68%. The firm decreased its portfolio allocation in CTVA by 5.17% over the last quarter.

VFINX - Vanguard 500 Index Fund Investor Shares holds 18,604K shares representing 2.71% ownership of the company. In its prior filing, the firm reported owning 18,131K shares , representing an increase of 2.54%. The firm decreased its portfolio allocation in CTVA by 5.95% over the last quarter.

Geode Capital Management holds 17,383K shares representing 2.54% ownership of the company. In its prior filing, the firm reported owning 17,704K shares , representing a decrease of 1.85%. The firm decreased its portfolio allocation in CTVA by 52.04% over the last quarter.

Corteva Background Information
(This description is provided by the company.)

Corteva Agriscience is a publicly traded, global pure-play agriculture company that provides farmers around the world with the most complete portfolio in the industry - including a balanced and diverse mix of seed, crop protection and digital solutions focused on maximizing productivity to enhance yield and profitability. With some of the most recognized brands in agriculture and an industry-leading product and technology pipeline well positioned to drive growth, the company is committed to working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva Agriscience became an independent public company on June 1, 2019 and was previously the Agriculture Division of DowDuPont.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.